Request Demo

Last update 08 May 2025

JK-279

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization-

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC12H10N4O

InChIKeyIHFPNTITRJDDEC-UHFFFAOYSA-N

CAS Registry219809-91-3

100 Clinical Results associated with JK-279

100 Translational Medicine associated with JK-279

100 Patents (Medical) associated with JK-279

Literatures (Medical) associated with JK-279

05 Dec 2018·Chemistry – A European JournalQ2 · CHEMISTRY

Versatile Coordination of Azocarboxamides: Redox‐Triggered Change of the Chelating Binding Pocket in Ruthenium Complexes

Q2 · CHEMISTRY

Article

Author: Košmrlj, Janez ; Lahiri, Goutam Kumar ; van der Meer, Margarethe ; Sarkar, Biprajit ; Beerhues, Julia ; Gazvoda, Martin ; Schweinfurth, David ; Klein, Johannes

AbstractAzocarboxamides occupy a special place among azo ligands owing to their versatility for metal coordination. Herein ruthenium complexes with two different azocarboxamide ligands that differ in the presence (or not) of a coordinating pyridyl heterocycle are presented. By making full use of the O,N(amide), N(azo), and N(pyridyl) coordinating sites, the first diruthenium complex that is bridged by an azo ligand containing two different binding pockets was obtained. Moreover, it was conclusively proven that, in the mononuclear complexes, oxidation at the ruthenium center leads to a complete change of coordination at the chelating binding pocket. The complexes were characterized by NMR spectroscopy, mass spectrometry, and single‐crystal X‐ray diffraction. Additionally, the mechanism of the aforementioned redox‐triggered change in the chelating binding pocket and the electronic structures of all the complexes were investigated by a combination of electrochemistry, UV/Vis/NIR/EPR spectroelectrochemistry, and DFT calculations. This is first instance in which a redox‐driven change in the complete chelating binding pocket has been observed in a ruthenium complex as well as with azo‐based ligands. These results thus show the potential of these versatile azocarboxamide ligands to act as redox‐driven switches with possible relevance to electrocatalysis.

12 Sep 2016·Organometallics

Ruthenium Azocarboxamide Half-Sandwich Complexes: Influence of the Coordination Mode on the Electronic Structure and Activity in Base-Free Transfer Hydrogenation Catalysis

Author: Urankar, Damijana ; Sarkar, Biprajit ; Sommer, Michael G. ; Bubrin, Martina ; Marinova, Sofiya ; Schweinfurth, David ; Košmrlj, Janez ; Krafft, Michael J.

Azocarboxamides were used as chelating ligands in ruthenium half-sandwich complexes.The synthesis and characterization of two new complexes with an unprecedented coordination motif are presented together with an in-depth investigation of two recently published complexes.Three different coordination modes of the ligands were realized, as evident by NMR spectroscopy and single-crystal x-ray diffraction.The use of base during the synthesis leads to a coordination of a deprotonated ligand, while the introduction of addnl. donor atoms results in a noncoordinated amide group.The first systematic exptl. (cyclic voltammetry and UV-vis-NIR and EPR spectroelectrochem.) and theor. (DFT) investigation of the electronic structure of metal complexes bearing this redox-active ligand class is presented, revealing redox processes with ligand contribution.The absorption spectra and electrochem. are mainly determined by the protonation state of the ligand.While complexes 2[PF₆], 3[PF₆], and 4[PF₆] with neutral azocarboxamides show similar electronic spectra and cyclovoltammograms, the incorporation of a deprotonated monoanionic ligand in complex 1 leads to significant changes of these properties.In contrast, the catalytic activity in the base-free transfer hydrogenation reaction is mainly dependent on the coordination of the amide group, with only minor effects of the protonation state.While complexes 3[PF₆] and 4[PF₆], with an uncoordinated amide group, are inactive without the addition of base, complexes 1 and 2[PF₆], with a metal-bound amide group, show activity under base-free conditions.The impact of the position of the amide group together with the detection of metal hydride species in ¹H NMR spectroscopy suggests the operation of metal-ligand bifunctional catalysis to take place when no base is added.

01 Mar 2014·European Journal of Medicinal ChemistryQ1 · MEDICINE

Biological evaluation of diazene derivatives as anti-tubercular compounds

Q1 · MEDICINE

Article

Author: Košmrlj, Janez ; Cappoen, Davie ; Urankar, Damijana ; Uythethofken, Cynthia ; Kočevar, Marijan ; Majce, Vita ; Polanc, Slovenko ; Mathys, Vanessa ; Verschaeve, Luc ; Huygen, Kris

Despite efforts made in chemotherapeutic research in the past and present, Mycobacterium tuberculosis (M.tb), the etiological agent of tuberculosis, still causes more than a million deadly casualties each year, second only to HIV. The rapid generation and spread of drug resistant strains, a problem exacerbated by co-infection with HIV demands further efforts in the investigation of novel classes of anti-tubercular compounds. A library of eight substituted diazenecarboxamides, three carbamoyldiazenecarboxylates and four diazene-1,2-dicarboxamides was synthesized in a straightforward manner followed by a biological evaluation of the compounds. We observed minimal inhibitory concentrations below 10 μg/mL against the H37Rv lab strain of M.tb. Three compounds that showed a potency of 90% growth inhibition of M.tb at a concentration lower than 10 μg/mL were further evaluated and showed potency against other clinically relevant mycobacterial species such as Mycobacterium bovis, Mycobacterium avium and Mycobacterium ulcerans. The selected compounds were examined for acute cell toxicity on a murine macrophage like monocyte cell line J774 A.1 in which the cell viability was reduced by 50% at concentrations ranging from 7.4 μg/mL to 20.7 μg/mL. Neither of the three compounds showed signs of genotoxicity by VITOTOX or by Comet assay. The study was complemented by demonstration of the inhibition of intracellular replication of M.tb H37Rv inside J774 A.1 cells at 2 μg/mL concentration and the susceptibility of a MDR LAM-1 strain at concentrations between 5 and 1 μg/mL of the most active compound.

100 Deals associated with JK-279

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	Croatia	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

JK-279

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation